Author

Courtney Frederick

Observed names: Courtney E. Frederick, Frederick E Courtney, Frederick, Courtney

Institution: Yale University

Observed institutions: Brown University, Yale Cancer Center, Yale University

OpenAlex ID: A5114086966

Melanopsin Ganglion Cells Use a Membrane-Associated Rhabdomeric Phototransduction Cascade

2008 · Dustin M. Graham, Kwoon Y. Wong, et al. · Journal of Neurophysiology · 201

Synaptic Ribbons Require Ribeye for Electron Density, Proper Synaptic Localization, and Recruitment of Calcium Channels

2016 · Caixia Lv, William J. Stewart, et al. · Cell Reports · 74

Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer

2021 · Julia Foldi, Andrea Silber, et al. · npj Breast Cancer · 71

Ribbon Synapses and Retinal Disease: Review

2023 · Courtney E. Frederick, David Zenisek · International Journal of Molecular Sciences · 22

Single-arm, neoadjuvant, phase II trial of pertuzumab and trastuzumab administered concomitantly with weekly paclitaxel followed by 5-fluoruracil, epirubicin, and cyclophosphamide (FEC) for stage I–III HER2-positive breast cancer

2018 · Julia Foldi, Sarah Mougalian, et al. · Breast Cancer Research and Treatment · 19

Safety of MEDI4736 (anti-PD-L1 antibody) administered concomitant with weekly nab-paclitaxel and dose dense doxorubicin/cyclophosphamide (ddAC) as neoadjuvant chemotherapy for stage I-III triple negative breast cancer (TNBC): A Phase I/II trial.

2017 · Lajos Pusztai, Andrea Silber, et al. · Journal of Clinical Oncology · 17

Durvalumab (MEDI4736) concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast cancer (TNBC).

2018 · Lajos Pusztai, Erin Wysong Hofstatter, et al. · Journal of Clinical Oncology · 9

The Effects of Aging on Rod Bipolar Cell Ribbon Synapses

2023 · Abhishek P Shrestha, Nirujan Rameshkumar, et al. · Cells · 8

Abstract PD1-01: Durvalumab (MEDI4736) concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast cancer (TNBC)

2020 · Lajos Pusztai, Emily Reisenbichler, et al. · Cancer Research · 8

Author Correction: Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer

2022 · Julia Foldi, Andrea Silber, et al. · npj Breast Cancer · 4

The Effect of Black Cohosh on Ki67 expression and Tumor Volume: A Pilot Study of Ductal Carcinoma in Situ Patients

2022 · Amelia A. Trant, Anees Chagpar, et al. · Integrative Cancer Therapies · 2

Metadata record for the manuscript: Single arm neoadjuvant Phase I/II study of durvalumab plus weekly nab-paclitaxel and dose dense doxorubicin/cyclophosphamide for stage I-III triple negative breast cancer

2020 · Foldi, Julia, Silber, Andrea, et al. · Figshare · 1

Pathologic complete response (pCR) rates after neoadjuvant pertuzumab (P) and trastuzumab (H) administered concomitantly with weekly paclitaxel (T) and 5-fluorouracil/epirubicin/cyclophosphamide (FEC) chemotherapy for clinical stage I-III HER2-positive breast cancer.

2017 · Julia Foldi, Sarah Schellhorn Mougalian, et al. · Journal of Clinical Oncology · 1

3571 Expression profile of the ribbon synapse protein Ribeye in the zebrafish

2019 · Courtney Frederick, David Zenisek · Journal of Clinical and Translational Science

Mechanisms of Melanopsin Photoresponse Termination: Biochemical Analysis of the Intrinsically Photosensitive Retinal Ganglion Cell Photopigment

2013 · Frederick, Courtney

Arrestin and Response Termination in Ganglion-cell Photoreceptors

2009 · Courtney Frederick, Shi-Jun Weng, et al. · Investigative Ophthalmology & Visual Science

Works count: 16

Citation count: 437

H-index: 8

I10-index: 6